The US approved lecanemab to slow cognitive decline among people with early Alzheimer's, but not everyone is convinced the drug has that big of an impact – not to mention concerns over its safety and practicality ⌘ Read more
The US approved lecanemab to slow cognitive decline among people with early Alzheimer's, but not everyone is convinced the drug has that big of an impact – not to mention concerns over its safety and practicality ⌘ Read more